Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
1.150
+0.030 (2.66%)
Nov 7, 2024, 11:25 AM EST - Market open

Company Description

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide.

The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.

It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.

The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women’s healthcare provider organizations.

Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Femasys Inc.
Femasys logo
Country United States
Founded 2004
IPO Date Jun 18, 2021
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 34
CEO Kathy Lee-Sepsick

Contact Details

Address:
3950 Johns Creek Court, Suite 100
Suwanee, Georgia 30024
United States
Phone 770 500 3910
Website femasys.com

Stock Details

Ticker Symbol FEMY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $13.00
CIK Code 0001339005
CUSIP Number 31447E105
ISIN Number US31447E1055
Employer ID 11-3713499
SIC Code 3841

Key Executives

Name Position
Kathy Lee-Sepsick M.B.A. Founder, President, Chief Executive Officer and Director
Dov Elefant Chief Financial Officer
Daniel Scott Currie Chief Operating Officer, Senior Vice President and Secretary
Mary An Merchant J.D., Ph.D. Vice President of Counsel and Intellectual Property
Sue Owens Vice President of Sales
Naomi Phaneuf Vice President of Marketing
Dr. Jeffrey Marcus M.D., M.S. Chief Medical Advisor
Christine Thomas Senior Vice President of Regulatory and Clinical Affairs
Dr. James H. Liu M.D. Chief Medical Officer
Richard Spector Chief Commercial Officer

Latest SEC Filings

Date Type Title
Oct 29, 2024 8-K Current Report
Sep 11, 2024 8-K Current Report
Sep 9, 2024 8-K Current Report
Aug 30, 2024 8-K Current Report
Aug 29, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 12, 2024 8-K Current Report
Jun 20, 2024 8-K Current Report
Jun 7, 2024 DEF 14A Other definitive proxy statements